After monoamines (MAs) are released at the synapse, they are removed by the actions of re-uptake transporters. In vertebrates, once in the pre-synaptic cell the MAs may either be reused, or degraded by monoamine oxidases or catechol-O-methyltransferase. Monoamine oxidase inhibitors (MAOIs) raise the levels of MAs by inhibiting the degradation of MAs. MAOIs are used to treat atypical depression, Parkinson's disease, and some psychoses. Unfortunately, MAOIs have significant and varied undesirable side effects. We are using known MA mutants to identify targets for three MAOIs (phenelzine, selegiline, tranylcypromine) in C. elegans. As predicted, MAOIs cause inhibition of thrashing, while pumping may be either stimulated or inhibited. As described previously, the
amx-2;
amx-1;
amx-3 triple mutant, which has deletions in three putative monoamine oxidases, is partially (but not completely) resistant to the effects of the drugs. We are currently examining the effects of MA synthesis or MA receptor mutations on drug sensitivity. We examined tranylcypromine resistance in
dop-1,
dop-2,
dop-3 single, double, and triple mutants and have found that
dop-3 mutants (but not
dop-1 or
dop-2) are partially resistant. Mutations in either
ser-1 or
ser-7 did not cause resistance. We are currently examining mutants with deletions in several octopamine or tyramine receptor genes (gifts of the Komuniecki lab). Our short-term plan is to determine if there is residual sensitivity to the drug when we simultaneously disrupt as many MAOI targets as possible. If there is residual sensitivity, we plan to use multiple mutants to identifying novels targets of MAOs that may be important for their affects on humans.